Study Sponsor: Teva Pharmaceuticals
Phase: Phase II, Safety
Clinical Sites in NC: None
The purpose of the LEGATO-HD trial is to see what effect different doses of an investigational drug called laquinimod may have on people with Huntington’s disease (HD) after 12 months of administration. You may be eligible to participate in the study if you are between the ages of 18 and 55 and have HD.